TACSTD2 and urinary bladder carcinoma: Third, considering that the response rate of patients with advanced bladder cancer to sacituzumab govitecan was limited to 27% in the TROPHY-U-01 trial [29], the expression of Trop-2 does not ensure the efficacy of sacituzumab govitecan.